FDA: Cases of Breast Implant-Related SCC, Various Lymphomas Reported
Following an initial extensive review, the Agency identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.
Skin Cancer
Review Profiles Open-Access Datasets With Skin Cancer Images
Darker skin types underrepresented among publicly available skin image datasets used to inform skin cancer diagnosis
Relatlimab-Nivolumab Fixed-Dose Combo Gets Priority Review for Melanoma
The application is supported by data from the phase 2/3 RELATIVITY-047 trial.
Adjuvant Pembrolizumab Prolongs Relapse-Free Survival in Stage II Melanoma
Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
Nemvaleukin Alfa Fast Tracked for Mucosal Melanoma
Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
MPR Weekly Dose Podcast Episode 85
This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there’s updates to the cancer drug Keytruda.
Keytruda Approved for Locally Advanced Cutaneous Squamous Cell Carcinoma
Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response.
Clinical Challenge: Pigmented Plaque on the Upper Back
A 37-year-old woman seeks treatment for keratosis pilaris on her arms and shoulders when a clinician discovers a deeply pigmented lesion on her upper back.
Keytruda Approved for Cutaneous Squamous Cell Carcinoma
The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
